BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henri C, O’meara E, De Denus S, Elzir L, Tardif J. Ivabradine for the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy 2016;14:553-61. [DOI: 10.1586/14779072.2016.1165092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Dogheim GM, Khairat I, Omran GA, El-Haggar SM, Amrawy AME, Werida RH. Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients. Eur J Clin Pharmacol 2022. [PMID: 35238960 DOI: 10.1007/s00228-022-03290-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kumar V, Kumar G, Tiwari N, Joshi S, Sharma V, Ramamurthy R. Ivabradine as an Adjunct for Refractory Junctional Ectopic Tachycardia Following Pediatric Cardiac Surgery: A Preliminary Study. World J Pediatr Congenit Heart Surg 2019;10:709-14. [DOI: 10.1177/2150135119876600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Thorup L, Simonsen U, Grimm D, Hedegaard ER. Ivabradine: Current and Future Treatment of Heart Failure. Basic Clin Pharmacol Toxicol 2017;121:89-97. [DOI: 10.1111/bcpt.12784] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]